NCT03595683 - Pembrolizumab and EDP1503 in Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

November 2, 2027

Study Completion Date

November 2, 2027

Conditions

Melanoma (Skin)Melanoma

Interventions

DRUG

Pembrolizumab

200 mg given by intravenous (IV) infusion once every 3 weeks.

BIOLOGICAL

EDP1503

Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).

Trial Locations (1)

University of Chicago Medical Center, Chicago